Intellia Therapeutics

NTLAsupplier

Intellia Therapeutics is a leading CRISPR gene-editing company developing in vivo therapies that edit genes directly inside the body. Its NTLA-2001 for transthyretin amyloidosis was the first in vivo CRISPR therapy to show clinical proof of concept in humans.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($0.15B)

Data statis (memuat keuangan langsung…)

Collaboration & License Revenue (70%)

Grants & Other (30%)

Komposisi segmen dan pelanggan utama

Detail produk

NTLA-2002 (HAE Gene Editing)40%

In vivo CRISPR therapy for hereditary angioedema via liver-targeted gene knockout

NTLA-2001 (ATTR Gene Editing)35%

In vivo CRISPR therapy for transthyretin amyloidosis

Ex Vivo Cell Therapies15%

CRISPR-edited cell therapies for cancer and autoimmune disease

Hubungan Rantai Pasok

Mitra

Regeneron Pharmaceuticals

Co-development of ex vivo cell therapies

Dampak: Medium — Regeneron partnership for cell therapies

Pesaing

Novo Nordisk

Rare blood disorder therapies

Dampak: Potential future competition

Pfizer Inc.

Gene therapy approaches

Dampak: Competing in genetic medicine pipeline

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Intellia Therapeutics.

Info Perusahaan

Kantor Pusat

Cambridge, Massachusetts, USA

Didirikan

2014

Karyawan

750+

Situs Web

intelliatx.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor